February 11, 2019 08:46 AM EST

CureVac walks away from Arcturus' urea cycle disorder drug, but partnership remains intact

Natalie Grover

Reporter

Arcturus Therapeutics had a melodramatic 2018 — the San Diego biotech’s CEO Joseph Payne was asked to leave for putting his interests before the RNA company …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

CureVac walks away from Arcturus' urea cycle disorder drug, but partnership remains intact

Natalie Grover

Reporter

Sign up to read this article for free.

Novartis turns to BioAge for new targets based on longevity and exercise

Updated: Flagship gene therapy startup Ring Therapeutics nearly halves workforce as CEO departs

Post-Hoc: Biosecure is dead. Long live Biosecure?

US spent $450B on drugs last year, CMS says, with new obesity and diabetes drugs adding to total

Novartis, AbbVie and PhRMA secure 340B court win in West Virginia

Merck’s long-awaited obesity move is an oral GLP-1 from China

Cure­Vac walks away from Arc­turus' urea cy­cle dis­or­der drug, but part­ner­ship re­mains in­tact

Natalie Grover

Reporter

Sign up to read this article for free.

more like this

No­var­tis turns to BioAge for new tar­gets based on longevi­ty and ex­er­cise

Up­dat­ed: Flag­ship gene ther­a­py start­up Ring Ther­a­peu­tics near­ly halves work­force as CEO de­parts

Post-Hoc: Biose­cure is dead. Long live Biose­cure?

US spent $450B on drugs last year, CMS says, with new obe­si­ty and di­a­betes drugs adding to to­tal

No­var­tis, Ab­b­Vie and PhRMA se­cure 340B court win in West Vir­ginia

Mer­ck’s long-await­ed obe­si­ty move is an oral GLP-1 from Chi­na

CureVac walks away from Arcturus' urea cycle disorder drug, but partnership remains intact

Novartis turns to BioAge for new targets based on longevity and exercise

Updated: Flagship gene therapy startup Ring Therapeutics nearly halves workforce as CEO departs

Post-Hoc: Biosecure is dead. Long live Biosecure?

US spent $450B on drugs last year, CMS says, with new obesity and diabetes drugs adding to total

Novartis, AbbVie and PhRMA secure 340B court win in West Virginia

Merck’s long-awaited obesity move is an oral GLP-1 from China